What is the main business of 21 Medical Innovations?

The main business activity of 21 Medical Innovations focuses on wholesale of pharmaceutical goods.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on November 15, 2019.

Where is the headquarters located?

The headquarters is located at: ul. Skowronków 10, 58-500 Jelenia Góra.

Who is on the management board?

The management board consists of: Filip Skrzypiec (President of the Management Board).

What is the share capital?

The share capital of the company is PLN 5,000 (approx. $1,351).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.

What revenue was generated?

In 2025, the company generated total revenue of USD 1,560,341, representing an increase of 206.9% compared to 2024.

Yes, in 2025 the company was profitable, achieving a net profit of USD 257,250, meaning the company increased its profit by 71.8%.

What is the largest operating cost?

The largest operating cost category falls under other operating costs. This category amounted to USD 1,060,049 in 2025, representing 83% of all operating expenses.

21 Medical Innovationssp. z o.o.

Wholesale of pharmaceutical goods

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2019-11-15

Share capital

5,000.00 PLN

Registered address

ul. Skowronków 10, 58-500 Jelenia Góra, Poland

Financials

Revenue history (in k)

From the notes

Current income tax (CIT due)

$25,339

Filing timeliness

5 of 6 financial statements were filed late (the longest delay 172 days for 2021).

202511/09/2026
202430/10/2025
202328/10/2024
202221/09/2023
202103/01/2023
202027/07/2021

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Industry · Wholesale of pharmaceutical goods591 / 1,141

Top 52%

Division · Wholesale trade8,164 / 20,010

Top 41%

Sector · Wholesale and retail trade; repair of motor vehicles including motorcycles12,292 / 29,939

Top 41%

City · Jelenia Góra106 / 441

Top 24%

Voivodeship · Dolnośląskie5,391 / 23,931

Top 23%

Country · Poland71,499 / 298,279

Top 24%

Results vs industry

Revenue

This companyUSD 1.56mMedianUSD 1.07mAverageUSD 22.39m

Net profit

This companyUSD 257.25kMedianUSD 37.46kAverageUSD 877.59k

Operating costs

This companyUSD 1.28mMedianUSD 932.14kAverageUSD 21.07m

Assets

This companyUSD 436.93kMedianUSD 609.79kAverageUSD 11.84m

Industry

Authorized Representatives

Filip Skrzypiecage 47 – President of the Management Board

Manner of representation

If the management board consists of one member who is the President of the company, the company is represented by a one-person management board. If the management board is a multi-member management board, each member of the management board may represent the company independently.

Ownership

Owner	Shares	Share value	Stake
Filip Skrzypiecage 47	95	$1,283.09	95%
Others	5	$67.53	5%

Beneficial owners

Person	Rights

Bank accounts

Registered as a VAT taxpayer on 2024-01-01.

PKO Bank Polski
67 1020 2124 0000 8302 0427 6291

Debt

No entries in the National Debtors Register (KRZ).

Public aid

No public aid cases recorded in the last 10 years.

Competitors

Name	Revenue	Website
Beautyeurope.Eusp. z o.o.	$2,675,688.56	beautyeurope.eu
AVEC Pharmasp. z o.o.	$1,786,681.69	avecpharma.com
Phytopur Biosp. z o.o.	$1,672,156.55	phytopurbio.pl
Mitorssp. z o.o.	$1,655,432.81	mitors.pl
Prima-Pharmasp. z o.o.	$1,648,108.34	primapharma.pl
Equadentsp. z o.o.	$1,636,062.40	equadent.pl
Axpharmsp. z o.o.	$1,614,509.74	axpharm.eu
Magnus Medicalsp. z o.o. + limited partnership	$1,603,171.30	magnusmedical.pl
Novicaresp. z o.o.	$1,512,398.66	novicare.pl
Ntradesp. z o.o.	$1,002,487.20	ntrade.com.pl